Physician profile
Laura Wolf Caba
NPI 1316582968
$2,040.09
in general payments reported to CMS, 2019-2025
17 companies · $30.85 in 2025
The $30.85 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,787 · 2022: $205 · 2023: $17.22 · 2025: $30.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $475.11 | 2021-2022 | |
| Abbvie INC. | $423.84 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $324.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.94 | 2021 | |
| Esperion Therapeutics, INC. | $114.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $107.07 | 2021 | |
| Lilly USA, LLC | $89.19 | 2021-2022 | |
| Pfizer INC. | $60.31 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $57.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $42.49 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $39.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $37.33 | 2021 | |
| Novo Nordisk INC | $36.79 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $30.85 | 2025 | Assure Wcd |
| Amarin Pharma, INC. | $29.52 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.45 | 2021 | |
| Gilead Sciences, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Caba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.